IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs
December 13, 2025 updated by: Hospices Civils de Lyon
IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs
The principal scientific objective of the trial is to identify the factors that are associated with differential blood pressure responses between drugs. This may allow investigators to produce new hypotheses on the pathophysiology of hypertension and on the mechanisms of drug action.
These factors can be of different types:
- Environmental factors (sodium or alcohol intake);
- Morphological (height, weight, body mass index, body surface area);
- Initial blood pressure;
- Electrocardiogram (ECG) parameters of left ventricular hypertrophy;
- Biological parameters as the activity level of the renin angiotensin aldosterone system;
- Genetic polymorphisms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
139
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bron, France, 69677
- Hopital Louis Pradel
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 56 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants have to be 25 to 60 years of age
- Both genders
- Systolic blood pressure of 140 mmHg or above; diastolic blood pressure of 90 mmHg or above.
- Cardiovascular risk must not be high, to allow for two periods of 4 weeks of placebo without ethical concern.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
|
1.5 mg/day during 4 weeks
4 mg/day during 1 week then 8 mg/day during 3 weeks
1 pill/day during 1 week then 2 pills/day during 3 weeks
1 pill/day during 4 weeks
|
|
Experimental: Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
|
1.5 mg/day during 4 weeks
4 mg/day during 1 week then 8 mg/day during 3 weeks
1 pill/day during 1 week then 2 pills/day during 3 weeks
1 pill/day during 4 weeks
|
|
Experimental: Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
|
1.5 mg/day during 4 weeks
4 mg/day during 1 week then 8 mg/day during 3 weeks
1 pill/day during 1 week then 2 pills/day during 3 weeks
1 pill/day during 4 weeks
|
|
Experimental: Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
|
1.5 mg/day during 4 weeks
4 mg/day during 1 week then 8 mg/day during 3 weeks
1 pill/day during 1 week then 2 pills/day during 3 weeks
1 pill/day during 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood pressure at the end of each 4 week treatment period
Time Frame: 16 weeks
|
Change from baseline and after each 4 week treatment period
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Francois GUEYFFIER, MD, Hospices Civils de Lyon
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
August 9, 2005
First Submitted That Met QC Criteria
August 9, 2005
First Posted (Estimated)
August 10, 2005
Study Record Updates
Last Update Posted (Estimated)
December 19, 2025
Last Update Submitted That Met QC Criteria
December 13, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2003.340
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.